These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 29867930

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Leprosy reactions: The predictive value of Mycobacterium leprae-specific serology evaluated in a Brazilian cohort of leprosy patients (U-MDT/CT-BR).
    Hungria EM, Bührer-Sékula S, de Oliveira RM, Aderaldo LC, Pontes AA, Cruz R, Gonçalves HS, Penna ML, Penna GO, Stefani MM.
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005396. PubMed ID: 28222139
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil.
    Hungria EM, Oliveira RM, Penna GO, Aderaldo LC, Pontes MA, Cruz R, Gonçalves HS, Penna ML, Kerr LR, Stefani MM, Bührer-Sékula S.
    Infect Dis Poverty; 2016 Dec 06; 5(1):110. PubMed ID: 27919284
    [Abstract] [Full Text] [Related]

  • 7. Can anti-PGL-1 and anti-NDO-LID-1 antibody titers be used to predict the risk of reactions in leprosy patients?
    Devides AC, Rosa PS, de Faria Fernandes Belone A, Coelho NMB, Ura S, Silva EA.
    Diagn Microbiol Infect Dis; 2018 Jul 06; 91(3):260-265. PubMed ID: 29669693
    [Abstract] [Full Text] [Related]

  • 8. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
    Cruz RCDS, Bührer-Sékula S, Penna GO, Moraes MEA, Gonçalves HS, Stefani MMA, Penna MLF, Pontes MAA, Talhari S.
    An Bras Dermatol; 2018 Jun 06; 93(3):377-384. PubMed ID: 29924240
    [Abstract] [Full Text] [Related]

  • 9. Clinical pilot study: Clarithromycin efficacy in multibacillary leprosy therapy.
    Gunawan H, Sasmojo M, Putri HE, Avriyanti E, Hindritiani R, Suwarsa O.
    Int J Mycobacteriol; 2018 Jun 06; 7(2):152-155. PubMed ID: 29900892
    [Abstract] [Full Text] [Related]

  • 10. Patient profile and treatment satisfaction of Brazilian leprosy patients in a clinical trial of uniform six-month multidrug therapy (U-MDT/CT-BR).
    Ferreira IP, Buhrer-Sékula S, De Oliveira MR, Gonçalves Hde S, Pontes MA, Penna ML, Cruz R, Penna GO.
    Lepr Rev; 2014 Dec 06; 85(4):267-74. PubMed ID: 25675651
    [Abstract] [Full Text] [Related]

  • 11. Alterations to antigen-specific immune responses before and after multidrug therapy of leprosy.
    Freitas AA, Oliveira RM, Hungria EM, Cardoso LP, Sousa AL, Costa MB, Reed SG, Duthie MS, Stefani MM.
    Diagn Microbiol Infect Dis; 2015 Oct 06; 83(2):154-61. PubMed ID: 26233487
    [Abstract] [Full Text] [Related]

  • 12. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
    Cunha Mda G, Virmond M, Schettini AP, Cruz RC, Ura S, Ghuidella C, Viana Fdos R, Avelleira JC, Campos AA, Filho B.
    Lepr Rev; 2012 Sep 06; 83(3):261-8. PubMed ID: 23356027
    [Abstract] [Full Text] [Related]

  • 13. Brazilian clinical trial of uniform multidrug therapy for leprosy patients: the correlation between clinical disease types and adverse effects.
    Gonçalves Hde S, Pontes MA, Bührer-Sékula S, Cruz R, Almeida PC, Moraes ME, Penna GO.
    Mem Inst Oswaldo Cruz; 2012 Dec 06; 107 Suppl 1():74-8. PubMed ID: 23283457
    [Abstract] [Full Text] [Related]

  • 14. Utility of immunoglobulin isotypes against LID-1 and NDO-LID for, particularly IgG1, confirming the diagnosis of multibacillary leprosy.
    Marçal PHF, Fraga LAO, Mattos AMM, Menegati L, Coelho ADCO, Pinheiro RO, Sarno EN, Duthie MS, Teixeira HC.
    Mem Inst Oswaldo Cruz; 2018 Dec 06; 113(5):e170467. PubMed ID: 29513821
    [Abstract] [Full Text] [Related]

  • 15. Challenges and advances in serological and molecular tests to aid leprosy diagnosis.
    Lopes-Luz L, Saavedra DP, Fogaça MBT, Bührer-Sékula S, Stefani MMA.
    Exp Biol Med (Maywood); 2023 Nov 06; 248(22):2083-2094. PubMed ID: 38059475
    [Abstract] [Full Text] [Related]

  • 16. Immunochemotherapy with interferon-gamma and multidrug therapy for multibacillary leprosy.
    Barral-Netto M, Santos S, Santos I, von Sohsten R, Bittencourt AL, Carvalho EM, Barral A, Waters M.
    Acta Trop; 1999 Mar 15; 72(2):185-201. PubMed ID: 10206118
    [Abstract] [Full Text] [Related]

  • 17. Performance of serological tests PGL1 and NDO-LID in the diagnosis of leprosy in a reference Center in Brazil.
    Leturiondo AL, Noronha AB, do Nascimento MOO, Ferreira CO, Rodrigues FDC, Moraes MO, Talhari C.
    BMC Infect Dis; 2019 Jan 07; 19(1):22. PubMed ID: 30616580
    [Abstract] [Full Text] [Related]

  • 18. Use of anti-PGL-1 antibodies to monitor therapy regimes in leprosy patients.
    Zenha EM, Ferreira MA, Foss NT.
    Braz J Med Biol Res; 2009 Oct 07; 42(10):968-72. PubMed ID: 19784481
    [Abstract] [Full Text] [Related]

  • 19. Antigen-specific assessment of the immunological status of various groups in a leprosy endemic region.
    da Conceição Oliveira Coelho Fabri A, Carvalho AP, Araujo S, Goulart LR, de Mattos AM, Teixeira HC, Goulart IM, Duthie MS, Correa-Oliveira R, Lana FC.
    BMC Infect Dis; 2015 May 30; 15():218. PubMed ID: 26021317
    [Abstract] [Full Text] [Related]

  • 20. Seroreactivity to new Mycobacterium leprae protein antigens in different leprosy-endemic regions in Brazil.
    Hungria EM, Oliveira RM, Souza AL, Costa MB, Souza VN, Silva EA, Moreno FR, Nogueira ME, Costa MR, Silva SM, Bührer-Sékula S, Reed SG, Duthie MS, Stefani MM.
    Mem Inst Oswaldo Cruz; 2012 Dec 30; 107 Suppl 1():104-11. PubMed ID: 23283461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.